Syntekabio Inc.

Syntekabio Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Welcome to Syntekabio Inc. – Your Leading AI Drug Discovery and Development Partner Syntekabio is a pioneering biotech firm headquartered in South Korea, with a vibrant presence in the United States. Our core mission is to redefine the landscape of drug discovery and development by harnessing the transformative potential of Artificial Intelligence (AI) and Next Generation Sequencing (NGS). At Syntekabio, we merge cutting-edge technologies, boasting a robust genomic database and AI-driven algorithms, with our proprietary supercomputing infrastructure. This synergistic approach empowers us to forecast and pinpoint promising new molecular entities, laying the groundwork for groundbreaking advancements in drug development. Driven by our commitment to innovation and patient-centric care, Syntekabio is dedicated to delivering novel therapies that extend and enhance lives. We actively seek collaborations with esteemed academic institutions, industrial partners, and government research labs to drive transformative advancements in medicine on a global scale. Conveniently located in New York City, Syntekabio USA serves as our hub for innovation and collaboration. Visit our website at www.syntekabio.com to explore our cutting-edge AI and NGS-based technologies and join us on our journey to shape the future of healthcare. "Syntekabio is at the forefront of pioneering AI-driven drug discovery and development initiatives across diverse domains."
Looking for a particular Syntekabio Inc. employee's phone or email?

Syntekabio Inc. Questions

News

Syntekabio Begins Full-Scale Operation of AI-Driven Asset Program - The National Law Review

Syntekabio Begins Full-Scale Operation of AI-Driven Asset Program The National Law Review

MetaVia, Syntekabio Partner to Expand Indications for Oral MASH Drug Using AI Drug Discovery - Pharmaceutical Executive

MetaVia, Syntekabio Partner to Expand Indications for Oral MASH Drug Using AI Drug Discovery Pharmaceutical Executive

Syntekabio Appoints Joonhyuk Choi, Former Target Health CEO, as Head of US Operations - ACCESS Newswire

Syntekabio Appoints Joonhyuk Choi, Former Target Health CEO, as Head of US Operations ACCESS Newswire

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 - PR Newswire

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 PR Newswire

Syntekabio names former Target Health CEO Choi to lead US offshoot - koreabiomed.com

Syntekabio names former Target Health CEO Choi to lead US offshoot koreabiomed.com

Syntekabio bets $3.1 mil. on US biotech to turn gut bugs into AI-driven immune meds - koreabiomed.com

Syntekabio bets $3.1 mil. on US biotech to turn gut bugs into AI-driven immune meds koreabiomed.com

ETRI Invites Forward-Looking Collaboration Partnership With Startups, Global Enterprises, and Universities - Business Wire

ETRI Invites Forward-Looking Collaboration Partnership With Startups, Global Enterprises, and Universities Business Wire

Syntekabio shares spike as AI drug discovery edges closer to real-world impact - koreabiomed.com

Syntekabio shares spike as AI drug discovery edges closer to real-world impact koreabiomed.com

Syntekabio, Teams Up with MSKCC for Next Cancer Drug - 팜이데일리

Syntekabio, Teams Up with MSKCC for Next Cancer Drug 팜이데일리

Syntekabio Reports Q1 Revenue Surge, 5x Last Year’s Total - 팜이데일리

Syntekabio Reports Q1 Revenue Surge, 5x Last Year’s Total 팜이데일리

Top Syntekabio Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant